0      0

AM21-45: New Developments in Optimizing Transfusion Management for Major Bleeding: "One Size Does Not Fit All Causes"

‐ Oct 19, 2021 4:45pm

Expiration Date: Dec 31, 2023

Credits: None available.

This proposed session will explore recent developments in our understanding of the effect of transfusion interventions and diagnostic tests in major bleeding. A common massive hemorrhage protocol cannot be recommended for all causes of major bleeding, and interventions need to be tailored by cause of bleeding. For example, patients with major bleeding due to gastrointestinal need a different management approach to those with obstetric bleeding or trauma (red cell transfusions, tranexamic acid). Many centers that treat massively bleeding patients rely on viscoelastic hemostatic assays to provide information about the coagulation status of their patients. Recently a large randomized trial of injured patients found that bleeding and survival was not different between patients resuscitated with either a viscoelastic or conventional coagulation strategy. This talk will review this and other studies on diagnostic tests and discuss our current standards for monitoring major bleeding.

To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.

Learning Objectives:

  • Interpret the evidence for different interventions and blood components that are available for resuscitating massively bleeding patients (trauma, gastrointestinal, obstetric) and what transfusion thresholds are indicated for these patients
  • Appraise results from the latest clinical trials evaluating viscoelastic or conventional coagulation testing strategies for monitoring resuscitation in massively bleeding patients
  • Translate the outputs of the session into practical changes to local policies of guidelines for the support of patients with major bleeding




  • Simon Stanworth, FRCP FRCPath DPhil:
    Nothing to Disclose
  • Monica Pagano, MD:
    Nothing to Disclose
  • Mark Yazer, MD:
    Consultant, Honoraria: Grifols, Macopharma, Octapharma, Terumo, Haemonetics, Cook Biotech, Verax Biomed, New Health Sciences, Aktivax, Cerus

All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.

Credits Available

AM21-45: New Developments in Optimizing Transfusion Management for Major Bleeding: "One Size Does Not Fit All Causes" Evaluation